98%
921
2 minutes
20
This retrospective study was performed to determine the incidence, timing, and clinical manifestations of major hemorrhagic events following percutaneous solid organ biopsy procedures in 32,331 cases performed between January 9, 2005, and September 8, 2023. Bleeding was categorized using the Common Terminology Criteria for Adverse Events (CTCAE). Major hemorrhage occurred in 139 cases (0.4%) and was most common after splenic biopsy (7/197, 3.6%) and native kidney parenchymal biopsy (41/4,108, 1.0%). Bleeding manifested within 1 hour in 60 cases (43%), between 1 and 2 hours in 15 cases (11%), between 2 and 24 hours in 46 cases (33%), and >24 hours in 18 cases (13%). Pain and hemodynamic instability were the most common manifestations, occurring in 96 (69%) and 63 (45%) patients, respectively. These findings confirm that the overall risk of major bleeding following solid organ biopsy is low, with splenic and renal biopsies entailing the highest risk. Delayed bleeding events are infrequent but should warrant consideration in guiding postprocedural follow-up.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jvir.2025.03.020 | DOI Listing |
Environ Sci Pollut Res Int
September 2025
Vellore Institute of Technology, Vellore, 632014, Tamil Nadu, India.
The significant global energy consumption strongly emphasizes the crucial role of net-zero or green structures in ensuring a sustainable future. Considering this aspect, incorporating thermal insulation materials into building components is a well-accepted method that helps to enhance thermal comfort in buildings. Furthermore, integrating architectural components made from solid refuse materials retrieved from the environment can have significant environmental benefits.
View Article and Find Full Text PDFToxicol Mech Methods
September 2025
Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.
Fluoropyrimidines are a class of chemotherapy drugs used to treat various solid tumors. 5-Fluorouracil (5-FU) an antimetabolite in the fluoropyrimidine family, which has shown remarkable efficacy against a variety of solid tumors, is a crucial medication in the treatment of cancer. However, severe organ toxicities frequently restrict its therapeutic potential.
View Article and Find Full Text PDFInfect Drug Resist
September 2025
Department of Infectious Diseases, Ningbo No.2 Hospital, Ningbo, 315010, People's Republic of China.
Objective: Multiple studies have confirmed that viral pneumonia is a high-risk factor for invasive pulmonary aspergillosis (IPA), this retrospective study aims to analyze the differences in clinical characteristics, prognosis, and high-risk factors for mortality between patients with influenza virus-associated pulmonary aspergillosis (IAPA) and those with COVID-19-associated pulmonary aspergillosis (CAPA).
Methods: Clinical data from IAPA and CAPA patients diagnosed at four hospitals were collected. The clinical characteristics and prognostic differences between the two groups were analyzed and compared, with Cox regression used to identify the risk factors for mortality.
Transpl Immunol
September 2025
Intensive Care, Royal Free Hospital, Hampstead, London, United Kingdom.
Background: Inflammatory injury in organ donors, particularly after brain death and during ischemia-reperfusion, contributes to graft dysfunction, rejection, and reduced survival. Statins, beyond their lipid-lowering role, exert pleiotropic anti-inflammatory and immunomodulatory effects, including IL-6 suppression, NF-κB inhibition, immune cell modulation, and potential alteration of exosome secretion.
Methods: Building upon this background, this narrative review synthesises preclinical and clinical evidence on pre-donation statin therapy in solid organ transplantation.
Transplant Direct
September 2025
Division of Transplantation, Department of General Surgery, Medical University of Vienna, Vienna, Austria.
Extracorporeal photopheresis (ECP) is a therapeutic intervention for modulating immune responses using an autologous apoptotic cell-based product, known as a photopheresate. The process of generating photopheresates offers attractive possibilities for manipulating distinct leukocyte subsets to either augment or dampen immune responses, depending on the disease context. This review discusses current uses of ECP as a cell-based therapy and introduces possible strategies to enhance the potency of photopheresates.
View Article and Find Full Text PDF